Strauss Borrelli PLLC, a leading data breach law firm, is investigating Intercept Pharmaceuticals, Inc. (“Intercept”) regarding its recent data breach. The Intercept data breach involved sensitive personal identifiable information and protected health information belonging to an undetermined number of individuals.
ABOUT INTERCEPT PHARMACEUTICALS, INC.:
Intercept is a biopharmaceutical company based in New Jersey. Founded in 2002, Intercept focuses on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, including primary biliary cholangitis and severe alcohol-associated hepatitis.3 Today, Intercept is leveraging its decades of research and background in bile acids and FXR agonism to expand its pipeline to deliver effective treatments for the growing number of people living with chronic liver diseases.4 Headquartered in Morristown, New Jersey, Intercept is a wholly owned subsidiary of Alfasigma S.p.A. and employs over 200 individuals.
WHAT HAPPENED?
Recently, Intercept discovered that it had experienced a data breach in which sensitive personal identifiable information and protected health information may have been accessed. As a result, Intercept began notifying individuals whose information may have been impacted. The type of personal information potentially exposed includes:
- Name
- Social Security number
- Driver’s license information
- Financial account information
- Medical record information
If you received a breach notification letter from Intercept Pharmaceuticals, Inc.:
We would like to speak with you about your rights and potential legal remedies in response to this data breach. Please fill out the form, below, or contact us at 872.263.1100 or sam@straussborrelli.com.
